

#5P7
RECEIPT 5/3/02

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE INDICATED BELOW.



DATE Feb. 25, 2002

PATENT
ATTN: APPLICATION BRANCH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re:	Patent Application of Thomas Maciag, et al.	: Group Art Unit: 1645	<p>COPY OF PAPERS ORIGINALLY FILED</p> <hr/>
Appln. No.:	10/022,554	: Examiner: Not Yet Assigned	
Filed:	December 17, 2001	:	
Title:	COMPOSITIONS, METHODS AND KITS RELATING TO THROMBIN DEGRADATION RESISTANT FIBROBLAST GROWTH FACTOR-1	: Attorney Docket No. 54474-5005	

REQUEST FOR CORRECTED FILING RECEIPT

Attached is the original filing receipt for the above-identified patent application.

In the section entitled "Assignment for Published Patent Application," please amend to read:

Maine Medical Center Research Institute and Repair, Inc.

Please make this correction and provide us with a corrected filing receipt.

Respectfully submitted,

THOMAS MACIAG, ET AL.

February 25, 2002
(Date)

By: Raquel M. Alvarez
RAQUEL M. ALVAREZ, Ph.D., J.D.
Registration No. 45,807
MORGAN, LEWIS & BOCKIUS, LLP
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: (215) 963-5000
Direct Dial: (215) 963-5403
Facsimile: (215) 963-5299
E-Mail: ralvarez@morganlewis.com
Attorney for Applicants

RECEIVED
MAR 28 2002
TECH CENTER 1600/2900


/dp
Enclosure

COPY OF PAPERS
ORIGINALLY FILED

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/022,554	12/17/2001	1645	1462	054474-5005	11	48	23



028977
MORGAN, LEWIS & BOCKIUS LLP
1701 MARKET STREET
PHILADELPHIA, PA 19103-2921

CONFIRMATION NO. 3856
FILING RECEIPT

OC000000007400672

Date Mailed: 01/31/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Thomas Maciag, Freeport, ME;
David S. Ettenson, Somerville, MA;
Wilson H. Burgess, Clifton, VA;
William N. Drohan, Springfield, VA;

TECH CENTER 1600/2900

RECEIVED
MAR 28 2002**Assignment For Published Patent Application**

Maine Medical Center Research Institute and Repair, Inc.;
Medical

Domestic Priority data as claimed by applicant**Foreign Applications****If Required, Foreign Filing License Granted 01/29/2002****Projected Publication Date: To Be Determined - pending completion of Missing Parts****Non-Publication Request: No****Early Publication Request: No****** SMALL ENTITY ******Title**

Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1

Preliminary Class

435

TECH CENTER 1600/2900

MAR 28 2002

RECEIVED

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).